Claudio Dansky Ullmann, MD

J. Stark Thompson, PhD
Non-Executive Chairman

Dr. Thompson has nearly five decades of corporate leadership and business management experience, dating back to when he joined the DuPont Company in 1967, where he spent more than 20 years. From 1988 until 2000, Dr. Thompson served as President, CEO and board member of Life Technologies, Inc. (LTI; NASDAQ: LTEK). Dr. Thompson has served on and led various boards of directors, including for companies such as Gene Logic, Inc. and Luminex Corporation (NASDAQ: LMNX). He received his BS degree from Muskingum University, and his MSc and PhD in physiological chemistry from The Ohio State University.

Claudio Dansky Ullmann, MD

Doug Doerfler
President and Chief Executive Officer

Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialisation and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company.

He also held various executive positions with Life Technologies, Inc. (now Thermo Fisher) that included leading its global businesses, mergers and acquisitions and its initial public offering (“IPO”). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization.

Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.

Claudio Dansky Ullmann, MD

Ron Holtz
Senior Vice President and Chief Accounting Officer

Mr. Holtz serves as MaxCyte’s Chief Financial Officer (CFO), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $150 million in debt and equity capital. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.

Claudio Dansky Ullmann, MD

Will Brooke
Non-Executive Director

Mr. Brooke is a Limited Partner of Harbert Management Corporation (“HMC”), which he co-founded in 1993. With approximately $6bn under management, HMC sponsors and co-invests in alternative asset strategies worldwide. Mr. Brooke organised and led one of HMC’s investment strategies, Harbert Venture Partners, for over a decade. He has been advising and investing in early-stage and growth companies for more than 20 years, and served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc., and Emageon Corporation. He also presently serves as a board member of KPX, LLC, which is an ESG advisory firm, serving the investment and advisory sectors. Mr. Brooke has previously served as HMC’s General Counsel, its Chief Operating Officer, and as Chairman of its Real Estate Services subsidiary. Prior to joining HMC, Mr. Brooke practiced law for a decade. He holds a JD and a BS, both from the University of Alabama.

Claudio Dansky Ullmann, MD

Richard Douglas, PhD
Non-Executive Director

Dr. Douglas formerly served as the Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation from 1989 until Genzyme was acquired by Sanofi in 2011. During this period, Dr. Douglas led numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. He had previously served in science and corporate development capacities at Integrated Genetics prior to its acquisition by Genzyme. He currently serves as an adviser to RedSky Partners, a biotechnology-focused advisory firm. He is Chairman of the Board of Aldeyra Therapeutics and on the Board of Novavax, Inc. Dr. Douglas received a PhD in Biochemistry from the University of California, Berkeley, and was a Post-Doctoral Fellow at California Institute of Technology in Leroy Hood’s laboratory. He has a degree in Chemistry from the University of Michigan, where he now serves as chair of the National Advisory Board for the Office of Technology Transfer, and also on two translational research oversight committees for the University’s Medical School.

Claudio Dansky Ullmann, MD

Stan Erck
Non-Executive Director

Mr. Erck is President and CEO, and Director of Novavax, Inc. Corporation. His 35 years of management experience in the healthcare and biotechnology industry include positions at Baxter International and Integrated Genetics, and as CEO and Director of Procept and Iomai. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, he has managed the process of developing companies from private funding through to IPO. Mr. Erck received his BS from the University of Illinois and an MBA from the University of Chicago.

Claudio Dansky Ullmann, MD

John Johnston
Non-Executive Director

After a career spanning some 30 years in the city of London, Mr. Johnston went on to hold non-executive positions in a wide range of industries including pharmaceutical, medical, energy and international hospitality. Immediately prior to this he was Managing Director of Institutional Sales at Nomura Code, and from 2008 to 2011, he was Director of Sales and Trading at Seymour Pierce. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. He joined Legg Mason Investors for three years as Director of Small Companies Technology and Venture Capital Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnston. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime. He began his investment career at the Royal Bank of Scotland.

Claudio Dansky Ullmann, MD

Art Mandell
Non-Executive Director

Mr. Mandell is a senior executive in the healthcare industry with more than 30 years of experience running companies, executing large corporate and business development deals in both the pharmaceutical and biotechnology sectors, and developing and commercializing a number of products. Mr. Mandell served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc. Prior to Prestwick, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., which was acquired by Astra Zeneca/MedImmune under his leadership. Before Cellective, Mr. Mandell served as President, Chief Executive Officer, and Director of Stemron Corporation, and as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. Mr. Mandell began his healthcare career at Syntex Pharmaceutical Corporation.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up